Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$223K Buy
3,914
+255
+7% +$15.3K 0.67% 49
2023
Q4
$230K Buy
+3,659
New +$207K 0.74% 50
2023
Q3
Sell
-8,350
Closed -$520K 58
2023
Q2
$520K Buy
8,350
+18
+0.2% +$1.2K 1.76% 32
2023
Q1
$602K Sell
8,332
-108
-1% -$8.45K 2.18% 23
2022
Q4
$678K Sell
8,440
-112
-1% -$8.57K 1.67% 21
2022
Q3
$570K Sell
8,552
-1,074
-11% -$79.3K 1.32% 25
2022
Q2
$731K Sell
9,626
-42
-0.4% -$3.19K 1.46% 16
2022
Q1
$768K Sell
9,668
-1,271
-12% -$92.4K 1.01% 28
2021
Q4
$803K Buy
+10,939
New +$737K 0.93% 36

Other funds holding INCY

Merlin Capital's INCY Position: Q1 2024 in Review

Merlin Capital increased its Incyte (INCY) stake by 7% in Q1 2024, buying an estimated $15.3K and bringing the position to 3,914 shares worth $223K. The position accounts for 0.67% of the portfolio, ranked #49.

Merlin Capital first reported a position in INCY in Q4 2021 and has held it in 9 quarters since. The position peaked at $803K in Q4 2021. 586 funds tracked by Wall St. Rank hold INCY as of Q1 2024.

  • Merlin Capital held 3,914 shares of Incyte worth $223K as of Q1 2024.
  • Merlin Capital bought 255 Incyte shares in Q1 2024, an estimated $15.3K.
  • Incyte made up 0.67% of Merlin Capital's portfolio in Q1 2024, its #49 holding.
  • Merlin Capital first reported a position in Incyte in Q4 2021 and has held it in 9 quarters since.
  • Merlin Capital's Incyte position peaked at $803K in Q4 2021.
  • 586 funds tracked by Wall St. Rank held Incyte as of Q1 2024.

Based on Merlin Capital's 13F filing for Q1 2024, filed 13 May 2024.